MicroRNA Drugs Startup Miragen Nears Close of Series A, Begins Defining Pipeline While specific details of Miragen’s planned pipeline are being kept under wraps, a company official said that the initial indication pursued would likely be heart failure, a condition one of the firm’s co-founders has linked to several microRNAs.
Nastech Confirms Change in Focus While Alnylam Addresses Partnering Concerns Although Nastech had said in an SEC filing that it would refocus on RNAi, the company’s CEO said that it would not continue developing non-RNAi programs after ongoing clinical trials are completed. Meanwhile, Alnylam’s CEO said that the firm’s track record of alliances speaks for itself.
![Publishing Systems Powered by iProduction [ralph]](/images-genomeweb/small_iproduction_logo.gif "Publishing Systems Powered by iProduction [ ralph]"){kind=logo}